These Blood Pressure Meds Fight Memory Loss
Almost half of U.S. adults have hypertension, a known risk factor for cognitive decline. A systematic review of 14 studies involving roughly 13,000 participants found that ACE inhibitors and angiotensin‑receptor blockers (ARBs) reduce the risk of mild cognitive impairment by about 20 percent. The protective effect appears tied to the ability of these drugs to cross the blood‑brain barrier. The analysis, published in *Hypertension*, highlights specific agents such as lisinopril, enalapril, valsartan and candesartan as potential dual‑action therapies.
The Public Health Issues Surrounding This Month’s CDC Vaccine Advisory Meeting
The CDC’s Advisory Committee on Immunization Practices will convene March 18‑19, 2026 to review COVID‑19 vaccine safety, long COVID, and potential revisions to its recommendation framework. Data show myocarditis rates among 12‑39‑year‑olds dropped from 38 per million after the original...
The Kaiser Settlement Should End the Guesswork in Medicare Advantage Oversight
The U.S. Department of Justice secured a $556 million settlement with Kaiser Permanente for allegedly submitting unsupported diagnosis codes to boost risk‑adjusted Medicare Advantage payments. The case, covering nearly a decade of overcoding, underscores the systemic pressure on clinicians to add...
HHS Launches Cybersecurity Module Within RISC 2.0 Toolkit
The Administration for Strategic Preparedness and Response (ASPR) has added a cybersecurity module to its Risk Identification and Site Criticality (RISC) 2.0 Toolkit, giving health systems a standardized way to assess cyber risk. The module uses a questionnaire scored against the...
Sword Health Evolves ‘Bloom’ Into an AI Operating System for Women’s Health
Sword Health announced that its Bloom product is evolving from a pelvic‑care solution into a comprehensive AI‑driven women’s health platform covering the entire life‑stage continuum. The expansion introduces a first‑of‑its‑kind menopause program that leverages “clinical memory” to create adaptive care...
Salesforce Announces 6 New Agentforce Health Agents and Integrations with Verily, HealthEx, and Viz.ai
Salesforce has launched Agentforce Health, a suite of six autonomous AI agents designed to relieve the administrative load on clinicians, payers, and public‑health agencies. The platform embeds deep integrations with HealthEx, Verily, Viz.ai, Informatica, MuleSoft and adheres to FHIR/TEFCA standards,...
CVS Health And Google Launch AI Business To ‘Personalize Healthcare’
CVS Health and Google announced a joint venture to launch Health100, an AI‑powered consumer health platform built on Google Cloud. The service will fuse CVS’s pharmacy, insurance and PBM data with Google’s Gemini models, Cloud Healthcare API and BigQuery to...
At CNBC Cures, Becky Quick Leads Clarion Call for Rare Disease Research
The CNBC Cures Summit opened with Becky Quick urging families and innovators to accelerate rare‑disease research. Speakers highlighted a widening gap between rapid scientific breakthroughs—gene therapies, AI‑driven diagnostics, and modular “nodal biology”—and an aging regulatory framework. Leaders from Biogen, the...
PointClickCare Announced the Launch of Discharge Intel at HIMSS26
PointClickCare unveiled Discharge Intel at HIMSS26, an AI‑driven tool that delivers clinical intelligence to health plans within 24 hours of a patient’s hospital discharge. The solution leverages the company’s nationwide network of over 30,000 providers and major U.S. health plans...
PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause
PepGen’s Phase 2 FREEDOM2 trial in myotonic dystrophy type 1 received a partial FDA clinical hold due to concerns over a sub‑chronic mouse study that showed blood‑pressure changes. The agency did not question the Phase 1 human data, and the company continues dosing...
Using Real World Data From the Patient Experience to Improve Drug Development
Randomized trials for non‑small cell lung cancer often miss real‑world nuances that affect patients' quality of life. Real‑world data (RWD) and social determinants of health (SDOH) expose hidden barriers such as transportation gaps and limited molecular testing access. Pharma can...
Automated CT Scan Analysis Could Fast-Track Clinical Assessments
NIH‑funded researchers at Stanford introduced Merlin, a foundation model that interprets 3D abdominal CT scans for a broad spectrum of clinical tasks. Trained on more than 15,000 scans paired with radiology reports and nearly one million diagnostic codes, Merlin outperformed specialist...
Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge
Roche announced a $480 million, five‑year investment in South Korea to build a national clinical‑trial ecosystem, fund R&D infrastructure, and train specialized personnel. The pledge also includes support for domestic biotech startups aiming for global markets. This move aligns with a...
EPtalk by Dr. Jayne 3/5/26
A recent LinkedIn post by Wayne Gillis points out that neither Rehoboth McKinley nor Great Falls Clinic uses Epic’s electronic health record platform, contradicting earlier assumptions. The post also notes that Rehoboth McKinley operates a Cerner/Oracle patient portal, highlighting ongoing...
Can GLP-1 Drugs Help Tackle Addiction?
A new BMJ meta‑analysis of over 600,000 U.S. veterans with type‑2 diabetes found that patients prescribed GLP‑1 agonists such as semaglutide or tirzepatide were 14% less likely to develop substance‑use disorders (SUD) than those on SGLT2 inhibitors. Over a three‑year...
Airiver Medical Receives FDA Breakthrough Device Designation for Airiver DCB and Treats First Patient with Central Airway Stenosis
Airiver Medical announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation to its pulmonary drug‑coated balloon (DCB) for treating central airway stenosis. The company also enrolled and treated the first patient in a pivotal trial that will...
Q&A: AWS Launches Amazon Connect Health to Streamline Healthcare Workflows
Amazon Web Services unveiled Amazon Connect Health, an agentic AI platform that plugs directly into electronic health records to automate patient verification, appointment scheduling, ambient documentation, and medical coding. The service, built on FHIR standards and Amazon HealthLake, offers a...
Targeted Therapies to Join Chemo as Oncology Treatment Backbone
Targeted therapies are reshaping oncology, yet chemotherapy remains essential. Immune checkpoint inhibitors like Keytruda generate $31.7 bn sales in 2025 and cover more than 40 indications. The FDA granted 63 antibody‑drug conjugate review designations in 2024, nearly double the previous peak....
Suffolk and North East Essex ICB Publishes £5.2 Million Contract for GP IT
Suffolk and North East Essex Integrated Care Board has issued a £5.2 million contract to modernise GP IT systems in line with the Primary Care Digital Services Model. The three‑year agreement, starting 1 December 2026, can be extended to 2031 and requires a...
Hansa Closes on FDA Verdict for Transplant Drug Imlifidase
The FDA has begun reviewing Hansa Biopharma’s imlifidase, a drug that desensitises highly sensitised kidney‑transplant patients, with a decision expected by December 19, 2024. If approved, it would be the first U.S. therapy to improve transplant odds for the 10‑15 % of...
HTN Now: Exploring and Tackling the Real Pain Points Around the Use of Digital Systems
A recent HTN audience survey, presented by Aire Innovate’s Ian Dove and Fiona Costello, identified persistent pain points in NHS digital systems. Staff cite inadequate training, top‑down development, poor interoperability and extensive manual workarounds, while IT capacity backlogs stretch change...
Akeso Presents P-II (COMPASSION-03) Trial Data on Cadonilimab for R/M Cervical Cancer at ESGO 2026
Akeso presented Phase‑II COMPASSION‑03 data for cadonilimab in patients with recurrent or metastatic cervical cancer who progressed after platinum chemotherapy. The trial reported a median overall survival of 17.5 months across the cohort, with 24‑month OS rates of 40.9% irrespective...
Philips Launches Rembra CT System for Acute Imaging
Philips has introduced Rembra, a next‑generation CT system built for acute and high‑throughput imaging environments. The scanner delivers ultra‑fast reconstruction speeds of up to 106 images per second and can support as many as 270 examinations per day. It features...
Hampshire Hospitals Celebrates 100th Surgical Procedure Using Pioneering State-of-the-Art Robotic System
Surgeons at Hampshire Hospitals NHS Foundation Trust have performed their 100th operation using the da Vinci 5 robotic‑assisted surgical system, just six months after becoming the first UK NHS trust to install the next‑generation robot. The system, deployed at Basingstoke...
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
GAIA and Daiichi Sankyo Europe announced an exclusive partnership to commercialize lipodia, a next‑generation digital therapeutic for hypercholesterolemia, pending regulatory approval. The deal grants Daiichi exclusive rights in Germany with expansion mechanisms for other European markets, leveraging GAIA’s validated behavioral...
Listen: What To Do When Health Insurance Slips Out of Reach
Health insurance coverage is slipping for many Americans as ACA marketplace sign‑ups fell by roughly one million this year and federal subsidies expired, driving premiums higher. Stricter Medicaid eligibility rules further limit options for low‑income households. KFF Health News correspondent...
HUTCHMED Begins Phase I/IIa Trial of HMPL-A580 for Solid Tumours
HUTCHMED has launched a first‑in‑human Phase I/IIa trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in the United States and China. The multi‑centre, open‑label study will evaluate safety, tolerability, immunogenicity, pharmacokinetics and early efficacy across dose‑escalation and expansion cohorts. HMPL‑A580...
Affinia Receives FDA Fast Track Designation for AFTX-201
Affinia Therapeutics announced that the FDA has granted fast‑track designation to its gene‑therapy candidate AFTX‑201 for BAG3‑associated dilated cardiomyopathy. The one‑time intravenous treatment delivers a full‑length BAG3 transgene via an engineered capsid that requires doses five to ten times lower...
Guiding Nano Assembly for Drug Delivery with Machine Learning
Researchers repurposed the FAP inhibitor SP‑13786 as a co‑assembly excipient to create SP co‑assembled nanoparticles (SCAN) that encapsulate hydrophobic drugs. Using molecular dynamics and a random‑forest machine‑learning model, they identified 228 physicochemical descriptors that predict successful nano‑co‑assembly, highlighting aromaticity and...
Why the Future of MedTech Is Being Led by Consumers
MedTech is moving from a hospital‑centric model to a consumer‑driven ecosystem, with at‑home diagnostics, wellness tools, and direct‑to‑consumer devices reshaping adoption. Design teams must prioritize motivation, habit and identity over pure clinical protocol, making products feel like lifestyle accessories rather...
STAT+: Gilead and South Africa Are Negotiating a License for Local Production of New HIV Drug
Gilead Sciences is in talks with the South African government to issue a voluntary licence for the local manufacture of lenacapavir, a novel HIV‑prevention drug. The agreement would enable South African firms, identified with help from Unitaid and the US...
Using Clinical NLP to Unlock Untapped Quality Data for HEDIS Compliance
Tim O’Connell, CEO of emtelligent, argues that most HEDIS‑critical information resides in unstructured clinical text, not traditional fields. Over 80% of healthcare data is narrative, leaving a compliance gap that can cost plans millions in lower Star Ratings. He highlights...
Using Tiny Ripples at Skin Level to Monitor for Possible Health Problems Below
Caltech researchers unveiled visual surface wave elastography, a technique that captures imperceptible skin vibrations with a smartphone camera to infer the stiffness and thickness of underlying tissue. By applying phase‑based motion processing and spectral analysis, the method extracts subpixel movements...
New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers
The FDA released a draft Level 1 guidance titled “New Clinical Investigation Exclusivity (3‑Year Exclusivity) for Drug Products: Questions and Answers.” The document clarifies statutory and regulatory criteria for obtaining three‑year market exclusivity on new drug applications or supplements. It outlines...
Tracing Extracellular Vesicles' Journey From Cancer Cells to Urine
Researchers at the Institute of Science Tokyo directly traced small extracellular vesicles (sEVs) from tumors to urine in mouse models of brain, lung and pancreatic cancer. Using engineered RNA tracers and luminescent‑fluorescent reporters, they showed tumor‑derived sEVs appear in urine...
Methode Electronics Inc (MEI) Q3 2026 Earnings Call Transcript
Medtronic reported Q3 2026 revenue of $9 billion, up 8.7% YoY, driven by an 11% surge in its cardiovascular portfolio and an 80% jump in Cardiac Ablation Solutions (CAS) where pulse‑field ablation now accounts for 80% of the segment. Gross margin...
CorMedix Inc (CRMD) Q4 2025 Earnings Call Transcript
CONMED reported Q4 2025 revenue of $373.2 million, a 7.9% year‑over‑year increase, and full‑year sales of $1.375 billion, up 5.2%. Orthopedic sales jumped 12.1% in the quarter, while international sales surged 15.4%, offsetting modest U.S. growth. Adjusted EPS rose 6.7% to $1.43,...
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals reported $172 million total revenue for 2025, driven by $125 million from its menin inhibitor RevuForge and $152 million from chronic GVHD therapy Nictimvo. RevuForge saw 38% quarter‑over‑quarter revenue growth and a 35% rise in prescriptions, bolstered by an expanded NPM1...
Nutex Health Inc (NUTX) Q4 2025 Earnings Call Transcript
Sensus Healthcare reported Q4 2025 revenue of $4.9 million, an 84% decline from the prior year, driven by the loss of its largest customer. Gross margin fell to 38.8% as servicing costs rose, while the company posted a $3.2 million net loss....
TriSalus Life Sciences Inc (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences reported Q3 2025 revenue of $11.6 million, a 57% year‑over‑year increase, while adjusted EBITDA loss narrowed to $5.4 million despite one‑time study charges. Gross margin slipped to 84% as new product launches strained manufacturing efficiency, but cash burn improved,...
Aligos Therapeutics Inc (ALGS) Q4 2025 Earnings Call Transcript
Agilon Health reported FY 2025 revenue of $5.93 billion, with Q4 revenue of $1.57 billion, but both medical margin and adjusted EBITDA remained negative, driven by higher inpatient claims and market exits. The company cut operating expenses by $35 million and extended its...
Contineum Therapeutics Inc (CTNM) Q4 2025 Earnings Call Transcript
Compugen Ltd. reported a dramatic financial turnaround in its Q4 2025 earnings, posting a $56.8 million quarterly profit and $35.3 million annual profit after a year of losses. A $65 million upfront royalty monetization from AstraZeneca boosted cash to $145.6 million, extending the cash runway...
‘AI, AI And AI’: CommonSpirit Health at Home CEO On The Forces Shaping 2026
CommonSpirit Health at Home is charting a 2026 roadmap that moves care upstream by using EHR‑based eligibility triggers to engage patients earlier in hospice and home‑health pathways. The provider plans a measured AI rollout focused on predictive analytics and operational...
64K SF Boulder Lab Leased To Pharma Company: The Denver Deal Sheet
CordenPharma Colorado has signed a 15‑year lease for a 64,000 SF purpose‑built lab in Boulder’s Flatiron Park, expanding its peptide development capabilities adjacent to an existing manufacturing plant. The speculative building, completed in 2024, features adaptable lab grids, advanced utilities and specialized...
Best in KLAS 2026: Executive Insights for Strategic Healthcare Technology Investment
Best in KLAS 2026 delivers a data‑driven analysis of healthcare technology solutions, ranking platforms by performance ratings, measurable outcomes, and innovation trajectories. It aggregates validated customer feedback and market performance data to help executives de‑risk technology investments. The report highlights...
Reshaping Leukemia Treatment and QOL Through Improved PROM Data Integration
A recent Hematology Reports review examined 15 randomized trials that integrated patient‑reported outcome measures (PROMs) into leukemia research. The analysis found that PROMs such as EORTC QLQ‑C30 and EQ‑5D not only captured quality‑of‑life domains but also independently predicted overall survival...
Scale Ambient AI with Strategic Partnerships
Healthcare technology firms are increasingly embedding Ambient Clinical Intelligence (ACI) into EHR, telehealth, and care‑management platforms to cut administrative load and speed revenue cycles. Building ACI models internally demands extensive engineering resources, prompting many vendors to seek external expertise. Suki’s...
Report: 5 AI Agent Trends to Watch in Healthcare & Life Sciences
Google Cloud’s 2026 report spotlights five AI‑agent trends reshaping healthcare and life sciences, from automating clinical paperwork to accelerating drug discovery. The analysis stresses that unlocking AI value requires leaders to discard legacy mindsets and foster a culture that embraces...
GDUFA Type II API DMF Payment Receipts Report
The FDA’s GDUFA Type II API DMF payment report shows 385 payments in FY 2023, a dip to 264 in FY 2024, a rebound to 374 in FY 2025, and 90 early‑year payments in FY 2026. Monthly counts reveal a pronounced September 2023 spike of 103...
Fiscal Year 2026 Generic Drug Science and Research Initiatives Public Workshop - 06/08/2026
The FDA is holding its Fiscal Year 2026 Generic Drug Science and Research Initiatives public workshop on June 8‑9, offering both in‑person and virtual attendance. The two‑day event will review current research gaps and solicit stakeholder input to shape the FY 2027...